Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
December 29, 2022 13:45 ET
|
Vericel Corporation
Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating...
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
November 10, 2022 09:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel Reports Third Quarter 2022 Financial Results
November 09, 2022 07:55 ET
|
Vericel Corporation
Total Net Product Revenue of $38.6 Million MACI Net Revenue Increased 30% to $31.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vericel...
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
October 26, 2022 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
September 22, 2022 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
September 06, 2022 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel Reports Second Quarter 2022 Financial Results
August 03, 2022 07:55 ET
|
Vericel Corporation
Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) --...
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
July 21, 2022 16:05 ET
|
Vericel Corporation
Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two...
Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
July 20, 2022 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel Reports First Quarter 2022 Financial Results
May 04, 2022 07:55 ET
|
Vericel Corporation
First Quarter Total Net Revenue of $36.1 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in...